

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Peijia Medical Limited

### 沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

## VOLUNTARY ANNOUNCEMENT

### UNAUDITED OPERATING STATISTICS

#### FOR THE PERIOD FROM JANUARY 1, 2021 TO DECEMBER 31, 2021

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the year ended December 31, 2021, and the comparative figures as set out below.

#### For the period from January 1 to December 31

	2021	2020	change
	<i>RMB' million</i>	<i>RMB' million</i>	<i>%</i>
Revenue Pre-VAT	<b>Approximately 154.3</b>	Approximately 43.7	<b>Approximately 253.2</b>
Revenue	<b>136.5</b>	38.7	<b>253.2</b>

The increase in revenue pre-VAT and revenue was primarily attributable to: (i) commercialization of the first generation TAVR product TaurusOne® and the second generation retrievable TAVR product TaurusElite®; (ii) increased sales revenue of detachable coil and other existing neuro-interventional products including SacSpeed® Balloon Dilatation Catheter; and (iii) commercialization of multiple new neuro-interventional products including Tethys® Intermediate Catheter and Jasper® SS Detachable Coil.

The Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2021. The above operating information is provided for investors' reference only and it shall not be taken as a measure or indication of the Group's future financial performance.

**SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, January 27, 2022

*As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.*